Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets open in the red
Fri, 25 Apr 09:30 am

The major Asian stock markets have opened the day on a mixed note with stock markets in Hong Kong (down 1.4%) and Taiwan (down 1.9%) leading the losses. However, the stock markets in Japan (up 0.2%) and Indonesia (up 0.5%) have opened on a positive note. The Indian share markets have opened the day in the red. The sectoral indices were trading mixed with stocks in oil and gas and FMCG leading the losses. However, stocks in the banking and realty sector were leading the gains.

The Sensex today is down by around 40 points (0.2%), while the NSE-Nifty is down by about 13 points (0.2%). The midcap and smallcap stocks have however opened in the green with BSE Mid Cap and BSE Small Cap indices up by around 0.2% and 0.1% respectively. The rupee is currently trading at Rs 61.11 to the US dollar.

Energy stocks have opened the day mainly in the red with Mangalore Refinery and Petrochemicals Ltd (MRPL) and Cairn India Ltd leading the losses. However, Chennai Petroleum Corporation Ltd (CPCL) and Oil India Ltd have opened on a positive note. Cairn India Ltd has announced its results for the full year 2014 (FY14). For FY14, the revenues grew by 7.1% year on year (YoY) basis. The growth in the revenues was driven by increase in working interest volume to 137.1 kilo barrels of oil equivalent per day (kboepd) in FY 2014, from 127.8 kboepd in FY 2013 and due to benefit from rupee depreciation. In Rajasthan, the company achieved 200,000 boepd production milestone during the year. It has also added to its resource base with a success ratio of 50%, and has established six discoveries. Since the resumption of exploration in March 2013, the company has added over 1 billion barrels of oil equivalent in-place reserves to the existing 4.2 billion barrels of oil equivalent. The net profit for the year was up 3 % YoY. The company has declared a final dividend of Rs 6.50 per share for the year.

Indian pharma stocks have opened mainly on a mixed note with Strides Arcolab Ltd and Panacea Biotech Ltd leading the gains. However, Natco Pharma Ltd and Dishman Pharma Ltd were leading the losses. As per a leading financial daily, the pharma major Dr. Reddy's Laboratories (DRL) has recently launched Fenofibrate capsules in the US market. The drug is a therapeutic equivalent generic version of Antara capsules which is indicated to reduce cholesterol and triglycerides (fatty acids) in the blood has been approved by the United States Food & Drug Administration (USFDA). According to IMS Health, the Antara (fenofibrate) capsules brand and generic had U.S. sales of approximately US$ 74 m for the twelve months ending in February 2014.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open in the red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.